title: Comparison of the changes in lipid metabolism between hepatoma-bearing and lipopolysaccharide-treated rats.
abstract: To elucidate the mechanism for hyperlipidemia in the hepatoma-bearing state, changes in some parameters related to the lipid metabolism and serum tumor necrosis factor-alpha (TNF-alpha) level were examined in Donryu rats that had been subcutaneously implanted with an ascites hepatoma cell line of AH109A. These parameters were also examined in rats that had been given a single injection of lipopolysaccharide (LPS), a model for acute infection with TNF-alpha secretion into the blood circulation. The serum triglyceride and total cholesterol (Ch) levels were significantly higher in both the hepatoma-implanted and LPS-injected rats than in normal rats. The level of adipose tissue lipoprotein lipase was decreased by hepatoma implantation and LPS injection, while the hormone-sensitive lipase activity was increased by the same treatments. Fatty acid (FA) oxidation and Ch synthesis were also stimulated by both treatments. The serum TNF-alpha level was noticably elevated by hepatoma implantation and greatly by the LPS injection. This LPS injection increased hepatic FA synthesis. The serum high-density lipoprotein Ch level and hepatic Ch 7alpha-hydroxylase activity were not changed by the LPS injection. Hepatoma implantation led to hyperlipidemia and elevated the serum TNF-alpha level, as did the LPS injection.
authors.affiliation: Department of Applied Biological Science, Tokyo Noko University, Tokyo, Japan. masashi@iwate-pu.ac.jp
authors.forename: Masashi
authors.initials: M
authors.lastname: Kawasaki
authors.forename: Kazumi
authors.initials: K
authors.lastname: Yagasaki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Miura
authors.forename: Ryuhei
authors.initials: R
authors.lastname: Funabiki
mesh_terms: D000818:Animals; D001201:Ascites / Q000473:pathology; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D004435:Eating / Q000187:drug effects; D005227:Fatty Acids / Q000097:blood; D006949:Hyperlipidemias / Q000378:metabolism*; D050356:Lipid Metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008071:Lipoprotein Lipase / Q000187:drug effects / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000097:blood / Q000187:drug effects; D008079:Lipoproteins, VLDL / Q000097:blood / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010743:Phospholipids / Q000097:blood; D051381:Rats; D002787:Sterol Esterase / Q000187:drug effects / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects
chemical_list: D008076:Cholesterol, HDL; D005227:Fatty Acids; D008070:Lipopolysaccharides; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D002784:Cholesterol; D002787:Sterol Esterase; D008071:Lipoprotein Lipase